TBCRC 022 trial: what clinicians have said so far
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
- NCT01494662 ↗
- Completed
- Dana-Farber Cancer Institute
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on TBCRC 022 (neratinib plus capecitabine; neratinib; neratinib plus ado-trastuzumab emtansine in HER2-positive breast cancer with brain metastases) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TBCRC 022 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 YouTube videos, typically up to 18 once built | |
| 4 podcast episodes, typically up to 18 once built | |
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- HKI-272; Surgical Resection; Capecitabine; HKI-272; Ado-Trastuzumab Emtansine
- Arms
- Cohort 1 · Active comparator
- Cohort 2 · Active comparator
- Cohort 3a/3b · Active comparator
- Cohort 4a/4b/4c · Active comparator
- Enrollment
- 140
- Primary outcomes
- Objective Response Rate Per Composite Response Criteria
- Objective Response Rate Per RANO-BM Criteria
- Sponsor
- Dana-Farber Cancer Institute with Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc.
- Start
- Feb 2012
- Primary completion
- Feb 1, 2023
- Results posted
- Yes
- Registry record
- NCT01494662 · updated Jan 23, 2026
Publications
linked from the registry- Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (TBCRC). Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 Apr;20(2):145-151.e2. doi: 10.1016/j.clbc.2019.07.011. Epub 2019 Aug 22. PubMed 31558424
- Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12. PubMed 30860945
- Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1. PubMed 26834058